Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

摘要: This consensus statement, conceived as a joint initiative of the Spanish Society Pathology (SEAP) and Medical Oncology (SEOM), makes diagnostic treatment recommendations for management patients with advanced or metastatic melanoma based on current scientific evidence biomarker use. document thus provides an opportunity to improve healthcare efficiency resource use, which will benefit these patients. Based data available so far, this expert group recommends routinely testing BRAF mutation status, result affects subsequent therapeutic The analysis genetic alterations in KIT may be reasonable primary tumours acral mucosal sites chronically sun-exposed skin, condition, but not other types melanomas. panel believes that alterations, such NRAS status carrying mutations, GNAQ/GNA11 mutational PTEN, is currently indicated routine clinical practice, because results do influence planning at present time. Other important issues addressed are organisational requirements quality controls needed proper biomarkers, legal implications borne mind.